1 Commission fédérale pour la santé sexuelle. Prophylaxie post-exposition (PEP) au VIH en dehors du milieu médical. Forum Med Suisse. 2014;14:151–3.
2 US Food and Drug Adminstration FDA. Press Announcements – FDA approves first drug for reducing the risk of sexually acquired HIV infection. Available at:
https://wayback.archive-it.org/7993/20170112032741/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312210.htm.
3 Organisation mondiale de la santé. OMS | Lignes directrices unifiées – La prévention, le diagnostic, le traitement et les soins du VIH pour les populations clés. OMS 2014; disponible sur:
www.who.int/hiv/pub/guidelines/keypopulations/fr/.
4 US Public Health Service. Pre-exposure prophylaxis for the prevention of HIV infection in the United States – 2014. A clinical practice guideline. Available at:
www.cdc.gov/hiv/pdf/PrEPguidelines2014.pdf. Accessed 17 August 2015.
5 European Medicines Agency EMA. First medicine for HIV pre-exposure prophylaxis recommended for approval in the EU. 2016. Available at:
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2016/07/news_detail_002578.jsp&mid=WC0b01ac058004d5c1. Accessed 15 September 2016.
6 Commission fédérale pour la santé sexuelle. Recommandations de la Commission fédérale pour la santé sexuelle (CFSS) en matière de prophylaxie préexposition contre le VIH (PrEP) en Suisse. Bulletin OFSP. 2016; :77–9.
7 Mugwanya K, Baeten J, Celum C, et al. Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women. J Infect Dis. 2016; :jiw125.
8 Vernazza P, Hirschel B, Bernasconi E, Flepp M. Les personnes séropositives ne souffrant d’aucune autre MST et suivant un traitement antirétroviral efficace ne transmettent pas le VIH par voie sexuelle. Bulletin des médecins suisses. 2008:165–9.
9 Fonner VA, Dalglish SL, Kennedy CE, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016;30:1973–83.
10 Grant RM, Anderson PL, McMahan V, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14:820–9.
11 McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2015;387:57–60.
12 Cohen MS, Chen YQ, McCauley M, et al. Antiretroviral Therapy for the Prevention of HIV-1 Transmission. N Engl J Med. 2016;375:830–9.
13 Molina J-M, Capitant C, Spire B, et al. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med. 2015;373:2237–46.
14 Grant RM, Koester KA. What people want from sex and preexposure prophylaxis. current opinion in HIV and AIDS. 2016;11:3–9.
15 The Lancet Hiv. Time for NHS England to accept responsibility for PrEP. Lancet HIV. 2016;3:e397.